145 related articles for article (PubMed ID: 23471488)
1. A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes.
Ma J; Checklin HL; Wishart JM; Stevens JE; Jones KL; Horowitz M; Meyer JH; Rayner CK
Diabetologia; 2013 Jun; 56(6):1236-42. PubMed ID: 23471488
[TBL] [Abstract][Full Text] [Related]
2. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Xie C; Iroga P; Bound MJ; Grivell J; Huang W; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetologia; 2024 Jul; 67(7):1260-1270. PubMed ID: 38561463
[TBL] [Abstract][Full Text] [Related]
3. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
[TBL] [Abstract][Full Text] [Related]
4. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
5. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Deane AM; Chapman MJ; Fraser RJ; Burgstad CM; Besanko LK; Horowitz M
Crit Care; 2009; 13(3):R67. PubMed ID: 19439067
[TBL] [Abstract][Full Text] [Related]
6. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
7. Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial.
Jakubowicz D; Froy O; Ahrén B; Boaz M; Landau Z; Bar-Dayan Y; Ganz T; Barnea M; Wainstein J
Diabetologia; 2014 Sep; 57(9):1807-11. PubMed ID: 25005331
[TBL] [Abstract][Full Text] [Related]
8. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
9. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
DeFronzo RA; Buse JB; Kim T; Burns C; Skare S; Baron A; Fineman M
Diabetologia; 2016 Aug; 59(8):1645-54. PubMed ID: 27216492
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
12. Postprandial effects of a whey protein-based multi-ingredient nutritional drink compared with a normal breakfast on glucose, insulin, and active GLP-1 response among type 2 diabetic subjects: a crossover randomised controlled trial.
Sridonpai P; Prachansuwan A; Praengam K; Tuntipopipat S; Kriengsinyos W
J Nutr Sci; 2021; 10():e49. PubMed ID: 34290863
[TBL] [Abstract][Full Text] [Related]
13. Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial.
Jakubowicz D; Wainstein J; Ahren B; Landau Z; Bar-Dayan Y; Froy O
Diabetes Care; 2015 Oct; 38(10):1820-6. PubMed ID: 26220945
[TBL] [Abstract][Full Text] [Related]
14. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects.
Frid AH; Nilsson M; Holst JJ; Björck IM
Am J Clin Nutr; 2005 Jul; 82(1):69-75. PubMed ID: 16002802
[TBL] [Abstract][Full Text] [Related]
15. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.
Deane AM; Summers MJ; Zaknic AV; Chapman MJ; Fraser RJ; Di Bartolomeo AE; Wishart JM; Horowitz M
Crit Care; 2011; 15(1):R35. PubMed ID: 21255422
[TBL] [Abstract][Full Text] [Related]
16. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
17. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial.
Jakubowicz D; Wainstein J; Ahrén B; Bar-Dayan Y; Landau Z; Rabinovitz HR; Froy O
Diabetologia; 2015 May; 58(5):912-9. PubMed ID: 25724569
[TBL] [Abstract][Full Text] [Related]
18. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
[TBL] [Abstract][Full Text] [Related]
19. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
Juel CTB; Lund A; Andersen MM; Hansen CP; Storkholm JH; Rehfeld JF; van Hall G; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
Diabetologia; 2020 Jul; 63(7):1285-1298. PubMed ID: 32394228
[TBL] [Abstract][Full Text] [Related]
20. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
